AnodyneWiki

Spironolactone

Spironolactone
Spironolactone
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass416.60 g/mol [1]
AppearanceCrystals from methanol [1]
OdorMild mercaptan-like odor [1]
Melting point198-207 [1]
Boiling point134 °C [1]
DecompositionWhen heated to decomposition it emits toxic fumes of sulfoxides. [1]
SolubilitySoluble in most organic solvents [1]
Predicted LogP2.9 [1]
Structural Identifiers
[]
Molecular formulaC24H32O4S
IUPAC nameS-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
SMILESCC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
InChIInChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1
InChIKeyLXMSZDCAJNLERA-ZHYRCANASA-N
CAS number52-01-7
UNII27O7W4T232
PubChem CID5833
Pharmacokinetics[]
Elimination half-lifeSpironolactone: 1.4 hours, 7α-thiomethylspironolactone: 13.8 hours, 6β-hydroxy-7α-thiomethylspironolactone: 15.0 hours, Canrenone: 16.5 hours
MetabolismLiver, others:, • Deacetylation via carboxylesterase, • S-Oxygenation via flavin-containing monooxygenase, • S-Methylation via thiol S-methyltransferase, • Dethioacetylation, • Hydroxylation via CYP3A4, • Lactone hydrolysis via PON3
ExcretionUrine, bile
Routes of administrationBy mouth, topical
Toxicity
[]
Mouse:
- ip: 260 mg/kg
Rabbit:
- ip: 866 mg/kg
Rat:
- ip: 277 mg/kg
 [1]

Spironolactone (also known as Aldactone, Verospirone, Spirolactone, Spiresis, Uractone, Xenalon, spironolattone, Espironolactona, Spironolactonum or Abbolactone) is a antiandrogen, antimineralocorticoid and prodrug substance of the steroid class.

Chemistry

 []

Spironolactone is a single defined stereoisomer.

Spironolactone matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Aldosterone is a key hormone in the renin-angiotensin-aldosterone system. By binding to the mineralocorticoid receptor at the distal tubules and collecting duct, it causes sodium reabsorption and potassium secretion, increases vascular stiffness and remodelling, and activates pro-inflammatory pathways. Spironolactone and its active metabolites are aldosterone antagonists that produce a potassium-sparing diuretic effect. They competitively bind to receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents that act more proximally in the renal tubule. [1]

Metabolism

Spironolactone acts as a for:

Metabolic pathways []

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target10 (2 contraindicated)

Medical side effects []

51 side effects listed on drug labels in (spironolactone).

  • Agranulocytosis
  • Alopecia
  • Amenorrhoea
  • Anaphylactic shock
  • Ataxia
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Drug eruption
  • Diarrhoea
  • Dizziness
  • Somnolence
  • Eosinophilia
  • Toxic epidermal necrolysis
  • Dermatitis
  • Rash
  • Body temperature increased
  • Drug fever
  • Gastritis
  • Gynaecomastia
  • Headache
  • Hyperkalaemia
  • Hypersensitivity
  • Hypertrichosis
  • Renal failure acute
  • Muscle spasms
  • Cramp muscle
  • Lethargy
  • Leukopenia
  • Breast pain
  • Nausea
  • Pruritus
  • Renal failure
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Thrombocytopenia
  • Ulcer
  • Urticaria
  • Vasculitis
  • Vomiting
  • Menstruation irregular
  • Discomfort
  • Ill-defined disorder
  • Rash erythematous
  • Gastric haemorrhage
  • Semen analysis abnormal
  • Erectile dysfunction
  • Benign breast neoplasm
  • Gastrointestinal disorder
  • Breast cancer
  • Breast enlargement

Indications

  • Adenoma benign
  • Alkalosis hypokalaemic
  • Angina pectoris
  • Ascites
  • Benign essential hypertension
  • Cardiac failure
  • Cardiac failure congestive
  • Coma hepatic
  • Diabetes mellitus
  • Diabetic nephropathy
  • Digitalis intoxication (NOS)
  • Discomfort
  • Diuresis
  • Essential hypertension
  • Gravitational oedema
  • Hepatic cirrhosis
  • Hirsutism
  • Hyperaldosteronism
  • Hyperlipidaemia
  • Hypernatraemia
  • Hyperplasia adrenal
  • Hypertension
  • Hypokalaemia
  • Hypotension
  • Hypotensive
  • Hypovolaemia
  • Idiopathic edema
  • Malignant hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Oedema
  • Pre-eclampsia
  • Pregnancy
  • Primary hyperaldosteronism
  • Secondary aldosteronism

Subjective effects []

alina / Spironolactone []
Routes:
  • Oral (100.0mg)
emily / Spironolactone []
Routes:
  • Oral
Pilz / Spironolactone []
Routes:
  • Oral (100mg)
Source:
  • Spironolacton-ratiopharm 100mg tablets
Notes:
x86pup / Spironolactone []
Routes:
  • Oral

 []

  • United Kingdom: Spironolactone is Prescription only.[3]
  • United States: Spironolactone is Prescription only.
  • European Union: Spironolactone is Prescription only.[4][5]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5833, Spironolactone. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5833
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Spironolactone. UNII: 27O7W4T232. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/27O7W4T232
  3. Aldactone 25 mg Film-Coated TabletsSummary of Product Characteristics (SmPC). (emc). 3 February 2022. https://www.medicines.org.uk/emc/product/1619/smpc
  4. Qaialdo EPAR. European Medicines Agency (EMA). 25 July 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo
  5. Qaialdo. Union Register of medicinal products. 31 May 2023. https://ec.europa.eu/health/documents/community-register/html/h1731.htm

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 19:01:34
drugspromissing (no DrugsPRO reagent data)2026-11-20 19:01:30
erowidmissing (no Erowid substance of that name)2026-11-20 19:01:30
gsrsok2026-11-20 19:01:30
hmdbmissing (hmdb.ca refused automated access to HMDB0014565)2026-11-20 19:01:30
keggok2026-11-20 19:01:32
pubchemok2026-11-20 19:01:30
redditmissing (no r/tripreports posts mention it)2026-11-20 19:01:30
siderok2026-11-20 19:01:30
structureok2026-11-20 19:01:30
wikipediaok2026-11-20 19:01:30